Logo of National Resource Center on AD/HD
Home · Register · NRC Library    in Spanish
Ask a Question About AD/HD
About AD/HD Diagnosis and Treatment Dealing with Systems Educational Issues Living with AD/HD

"Latest News" Archive

2003 - 2004 - 2005 - 2006

2008

Feb. 20, 2008: FDA Proposes Guidance for Dissemination of Information on Unapproved Uses of Medical Products.

2007

Nov. 19, 2007: DEA Rule permits 90-day supply of Schedule II prescriptions (CHADD statement
Nov. 12, 2007: NIMH reports brain matures late in AD/HD; follows normal pattern
Nov. 5, 2007: NIMH study finds preschoolers with 3+ coexisting disorders do not respond to AD/HD meds
Aug. 15, 2007: NIMH study finds behavioral interventions effective for preschoolers with AD/HD
July 20, 2007: NIMH Issues Follow Up to Major AD/HD Study (the MTA Study); CHADD Comments
July 16, 2007: Child & Adolescent Psychiatrists Issue New Practice Parameter
June 22, 2007: FDA Issues Dietary Supplements Final Rule
March 21, 2007:  FDA Proposes New, Tougher Procedures for Membership on Advisory Committees
Feb. 23, 2007: FDA Issues Approval for Vyvanse
Feb. 21, 2007: FDA Directs AD/HD Drug Manufacturers to Develop Patient Medication Guides
Jan. 30, 2007: 
FDA Statement on Commitment to Drug Safety
Jan. 29, 2007: CHADD and Other Advocates Issue Joint Statement on Improving the Mental Health and Well-Being of America's Children

2006

Dec. 4, 2006: Statement of CHADD PAB on Environmental Factors and AD/HD
Oct. 16, 2006: NIMH Press Release: Preschoolers with AD/HD and Low Doses of Medication
Sept. 22, 2006: SAMHSA's DAWN Report on Emergency Room Visits and AD/HD Stimulant Medications
Aug. 21, 2006: FDA and GlaxoSmithKline Notify Health Professionals of Prescribing Changes for Dexedrine (dextroamphetamine sulfate)
Aug. 8, 2006: Novartis's FDA-approved Revised Label for Ritalin Products
June 1, 2006: GRATIS Guia Bilingüe Ahora Disponible // FREE Bilingual Education Guide Now Available
May 26, 2006: Health Canada Advisory on Rare Risks for AD/HD Medications
Feb. 14, 2006: CHADD Statement on Meeting of FDA Advisory Committee Recommendation

2005

Oct. 24, 2005: FDA Orders Discontinuation of Cylert (pemoline)
Sep. 29, 2005: FDA Issues Public Health Advisory on Strattera (atomoxetine)
Aug. 24, 2005: Health Canada allows Adderall XR back on Canadian market
Aug. 11, 2005: Transcript of FDA Pediatric Advisory Committee 6/30/05 Meeting re: Medication Labeling Changes
Feb. 10, 2005: Canada Suspends Sales of Adderall XR; Statement by FDA
Jan. 14, 2005: One Lot of Methylin Voluntarily Recalled

2004

Dec. 2004: "Black Box" Warning (from Attention! magazine)
Dec. 17, 2004: FDA Issues Talk Paper, New Warning About Strattera
Oct. 15, 2004: FDA Issues Public Health Advisory on Antidepressants and Children
Aug. 20, 2004: FDA Talk Paper Use of Antidepressant Medications for Children
July, 2004: FDA seeks Patient Representatives for Advisory Committee on AD/HD
April 5, 2004: Pediatrics study on TV Viewing and Attentional Problems
March 22, 2004: FDA Issues Advisory on Antidepressant Use
March 17, 2004: Federal Trade Commission Fines "Focus Factor" $1M - (for related info)

2003

Dec. 18, 2003: NRC Launches Online Library
May 20, 2003: The National Resource Center on AD/HD Holds Grand Opening Ceremony
Search:
Frequently Asked Questions
Is there a simple test to diagnose AD/HD?
Can you help me find a doctor or mental health professional?
What is Section 504?
My child has been diagnosed with AD/HD; isn't he automatically qualified for Section 504 services?
I'm an adult; doesn't AD/HD only affect children?
View all Frequently Asked Questions

Ask a question about AD/HD
CHADD

Print Page · Email Page · About Us · Contact Us
Terms of Use · Privacy Policy · Site Map
CHADD